Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Image of Carsten Reinhardt in suit outside a building

Theolytics, a biotech focused on developing curative cancer therapies in the form of best-in-class oncolytic viruses, today announced the Board appointment of Carsten Reinhardt MD PhD.

Dr Reinhardt, currently Chief Development Officer and Managing Director of NASDAQ-listed Immatics Biotechnologies GmbH, is a visionary oncology and biotech expert with extensive experience in translational development and early and late-stage clinical trial design progressing multiple biological compounds from early preclinical development through first-in-man studies towards approvals in the US and Europe.

Dr Reinhardt said, “I very much look forward to working with Theolytics, a company that is revolutionizing the discovery and development of more effective and safer oncolytic virus therapies. The company’s revolutionary adenoviral-based selection platform enables a target product profile led, highly specific approach to drug discovery and may overcome many of the current limitations of Immuno-oncology.”

For the full story click here.